Full View

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

CD DiNardo, IS Tiong, A Quaglieri… - Blood, The Journal …, 2020 - ashpublications.org
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …
被引用次数：514 相关文章

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

CD DiNardo, IS Tiong, A Quaglieri… - …, 2020 - mdanderson.elsevierpure.com
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

CD DiNardo, IS Tiong, A Quaglieri, S MacRaild… - …, 2020 - einstein.elsevierpure.com
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …
[HTML] nih.gov

[HTML][HTML] Myeloid Neoplasia: Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

CD DiNardo, IS Tiong, A Quaglieri, S MacRaild… - Blood, 2020 - ncbi.nlm.nih.gov
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

CD DiNardo, IS Tiong, A Quaglieri… - …, 2020 - researchinformation.amsterdamumc …
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

CD DiNardo, IS Tiong, A Quaglieri, S MacRaild… - …, 2020 - pubmed.ncbi.nlm.nih.gov
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

CD DiNardo, IS Tiong, A Quaglieri, S MacRaild… - 2020 - digital.library.adelaide.edu.au
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …
[HTML] sciencedirect.com

[HTML][HTML] Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

CD DiNardo, IS Tiong, A Quaglieri, S MacRaild… - Blood, 2020 - Elsevier
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

CD DiNardo, IS Tiong, A Quaglieri, S MacRaild… - Blood, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> The BCL-2 inhibitor venetoclax combined with
hypomethylating agents or low-dose cytarabine represents an important new therapy for …

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

CD DiNardo, IS Tiong, A Quaglieri, S MacRaild… - …, 2020 - researchwithrutgers.com
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …